1

TITLE PAGE

- 2 Manuscript Title- Optimal Systolic Blood pressure control after thrombectomy in acute
- 3 ischemic stroke-a systematic review and meta-analysis
- 4 Short title-Optimal Systolic blood pressure after thrombectomy

5 Authors and affiliations

Author	Qualification	Affiliation	Email IDs				
Baikuntha Panigrahi	MD,DM	Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029,India	baikunthap199@gmail.co m				
Rohit Bhatia*	MD,DM	Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029,India	rohitbhatia71@yahoo.com				
Partha Haldar	MD	Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi 110029,India	parthahaldar@outlook.co m				
Risha Sarkar	MA	Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029,India	risha98sarkar@gmail.com				
Imnameren Longkumer	PhD	Department of Neurology, All India Institute of Medical Sciences, New Delhi 110029,India	imna01lkr@gmail.com				

6 *Corresponding author

- 7 Dr.Rohit Bhatia
- 8 Professor
- 9 Room 603. 6th Floor
- 10 Department of Neurology
- 11 Neurosciences Centre
- 12 All India Institute of Medical Sciences
- 13 New Delhi 110029. India
- 14 Mail-rohitbhatia71@yahoo.com
- 15

16 Manuscript Metadata

- 17 Abstract word count-343 words
- 18 Manuscript Total Word count-4021 words
- 19 Tables-2
- 20 Figures-6
- 21 References-22

1 Optimal Systolic Blood pressure control after thrombectomy in acute

2 ischemic stroke-a systematic review and meta-analysis

3

4 Abstract

5 Background and Objectives

Although endovascular thrombectomy(EVT) is the standard of care for acute large vessel
occlusions(LVO), optimal systolic blood pressure (SBP) control post procedure has remained
elusive. Our study aimed to address the question of whether in adult patients of acute
ischemic stroke(AIS) who undergo EVT does an intensive SBP control as compared to a less
intensive SBP control/conventional control up to 24 hours post procedure lead to a good
functional outcomes defined by modified Rankin score(mRS) of 0-2 at 90days.

12

13 Methods

14 This PRISMA guidelines were followed for this review. Databases(PubMed, SCOPUS, 15 EMBASE, Google Scholar and Web of Science) were searched for English language articles 16 using predefined search terms till Sep 15 2023. The inclusion criteria consisted of 17 randomized controlled trials (RCTs) and observational studies(at least total 20patients) 18 analysing intensive vs conventional SBP control in AIS due to LVO post-EVT up to 24hours. 19 Studies without a separate comparison primary outcome data, comparing SBP control in AIS 20 due to LVO treated only with IV thrombolysis (IVT) without EVT, case series and case 21 reports were excluded. The primary outcome was the rate of functional independence defined 22 by mRS 0-2 at 90days. Risk of bias was assessed using the New Castle Ottawa scale(NOS) 23 for observational studies, and the revised Cochrane risk-of-bias 2 (ROB2) tool for RCTs.

24

25 Results

26 Twelve studies(n=5439 patients-eight observational and four RCTs) were included in the 27 final analysis. The primary outcome was not significantly different between both the 28 arms(RR:1.16;95%CI-0.98-1.37;p=0.08). There were no significant differences in the 29 mortality at 90days(RR:0.83;95%CI-0.68-1.02;p=0.08) and the risk of symptomatic 30 intracranial haemorrhage(RR:0.84;95%CI-0.61-1.16;p=0.29). Fewer patients required 31 decompressive surgery in the intensive arm(RR-0.40; 95%CI-0.25-0.66; p=0.0003). A 32 separate analysis for the primary outcome from pooled observational data favoured intensive 33 control(RR-1.34;95%CI-1.20-1.48; p<0.00001) and data from RCTs favoured conventional 34 control(RR-0.82;95%CI-0.72-0.93;p=0.003).

35

36 Conclusion

Neither intensive nor conventional SBP control resulted in better functional outcome in the
combined analysis of all studies. Although, observational studies favoured intensive control,
data from RCTs suggested conventional management as the preferred approach which could
currently be a pragmatic strategy. Further ongoing RCTs using homogenous SBP cut-offs
will provide more clarity on the ideal SBP target after EVT.

Keywords-Endovascular thrombectomy, Large Vessel Occlusion, Acute Ischemic Stroke,
 Systolic Blood pressure, modified Rankin Scale.

3 4

Introduction

5 6

7 Endovascular thrombectomy with or without thrombolysis is currently the standard of care in patients with acute ischemic stroke due to a large vessel occlusion.¹ However, even after 8 successful radiological evidence of reperfusion a proportion of patients do not achieve the 9 desired level of functional independence.² This is dependent on numerous modifiable, non-10 modifiable and unknown factors. Among these, blood pressure (BP) is a major modifiable 11 factor which influences the outcomes after a successful reperfusion.^{2,3} The interaction 12 between BP and outcomes is extremely complex as other critical factors including the 13 14 collateral status, size of the penumbra and degree of recanalization play a role in the final outcome.⁴ However, the optimal blood pressure after thrombectomy is not clear. The 2019 15 American Heart Association/American Stroke Association(AHA/ASA) guidelines for acute 16 17 ischemic stroke recommend that it is reasonable to maintain BP at $\leq 180/105$ mm Hg during and for 24 hours after the procedure (LOE-B-NR;COR-IIa)¹. It is well acknowledged in the 18 guideline that the data on optimal blood pressure target is sparse and the data supporting this 19 20 guideline was drawn from blood pressure management protocols in the thrombectomy trials. 21 Since a majority of the patients enrolled in the six hour time window trials had already received thrombolysis, the post thrombolysis blood pressure targets applied to them. 22 Additional data was obtained from the DAWN and ESCAPE trial protocols.^{5,6} The DAWN 23 protocol recommended the systolic BP (SBP) to be maintained at <140mmHg in the first 24 24hrs after the procedure.⁶ However, the ESCAPE protocol recommended the SBP to be 25 26 maintained at >150mmHg to maintain collateral perfusion.⁵

27 Since the last recommendations, multiple randomised and observational data has become 28 available with conflicting results which makes it imperative to perform a systematic review 29 and meta-analysis to carefully address this important question. We conducted this meta-30 analysis to address the question of whether in adult patients with an acute ischemic stroke due 31 large vessel occlusion who undergo thrombectomy does an intensive blood pressure 32 control (Target SBP cutoff as defined by the respective study or an upper limit of SBP target 33 for defining intensive control as <140mmHg) as compared to a less intensive blood pressure 34 control/conventional control(higher SBP targets or guideline recommended SBP control) up 35 to 24 hours after the procedure lead to a good functional outcome as defined by modified 36 Rankin score (mRS) of 0-2 at 90 days.

37

38 Methods

39

40 *Search strategy*

41 We used the standard PRISMA (Preferred Reporting Items for Systematic Reviews and 42 Meta-Analyses) guidelines for conducting and reporting our review (Checklist in 43 *Supplementary material-1*). The protocol was registered on PROSPERO 44 (https://www.crd.york.ac.uk/prospero/#myprospero) vide registration number-

1 CRD42023463173. An amendment was submitted on 28 January 2024 to define blood 2 pressure targets as per the respective study definition. A comprehensive preliminary search 3 was carried out by three authors (B.P, R.S and I.L) for English Language articles from 4 inception until September 15, 2023, using databases which included PubMed, SCOPUS, 5 EMBASE, Google Scholar, Web of Science and hand searching. The MeSH terms included 6 for the search string were - "Acute stroke", OR "Ischemic stroke" OR "cerebrovascular 7 accident" OR "cerebral infraction" AND "thrombectomy" OR "endovascular therapy" OR 8 "mechanical aspiration" OR "endovascular technique" OR "endovascular procedure" OR 9 "stent retriever" AND "blood pressure" OR "blood pressure monitor" OR "high blood 10 pressure" OR "low blood pressure" OR "hypertension". The search results obtained from the 11 various sources were imported to the Covidence software (https://www.covidence.org). 12 Duplicates were removed using the software automatically.

13

14 Screening and Eligibility criteria

15 Titles and abstracts were reviewed independently by four authors (B.P, RB, R.S, I.L) to 16 evaluate for inclusion and screening of full text. The review question and the PICO 17 statements are summarised in the form of a table (available as Supplementary material-2). 18 The inclusion criteria of the studies were-Randomized Controlled Trials (RCTs), 19 observational prospective studies, observational retrospective studies with at least a total of 20 20 patients, patients included in the study must have had a baseline mRS-0-1, patients with 21 Acute Ischemic Stroke (AIS) due to large vessel occlusion (LVO) involving either the 22 anterior or the posterior circulation and treated with thrombectomy using any technique with 23 or without bridging thrombolytic agent, systemic blood pressure monitoring during and at 24 least 24 hours after the procedure and functional outcomes using the mRS at 90days should 25 have been reported. Intensive control was defined as aggressive control of SBP to a 26 predefined target of <140mmHg or as described in the respective study with the use of anti-27 hypertensive drugs for up to 24 hours after a successful thrombectomy irrespective of 28 whether the patient received thrombolysis or not . Less Intensive or Conventional blood 29 pressure control was defined as a liberal SBP control strategy where SBP was not lowered 30 until it was >180mmHg as per guidelines. We excluded case series, case reports, studies 31 without a separate comparison outcome data between intensive and less intensive blood 32 pressure groups, studies comparing blood pressure control in AIS due to LVO treated only 33 with Intravenous thrombolysis (IVT) without Endovascular therapy (EVT) and studies 34 without a primary efficacy outcome data. The primary efficacy outcome was the proportion 35 of patients who had a mRS of 0-2 at 90days. Other safety outcomes that were analysed were 36 death at 90 days, development of symptomatic intracranial haemorrhage(sICH) and 37 requirement of decompressive surgery. Any discrepancies were resolved by R.B. Full texts 38 were retrieved for further consideration for inclusion in the study. Individual patient data was 39 not available for the study.

40

41 *Data Extraction*

42 The data was extracted on MS Excel (Ver 16.66.1).This included: the name of the journal, 43 year of publication, 1st author's name, study type- retrospective, prospective study or 44 randomized trial (monocentric or multicentric), number of patients, proportion of patients

with a history of hypertension, median NIHSS, stroke localization, intravenous thrombolysis use (if provided), recanalization rates, procedure time, number of patients in the intensive and conventional treatment arm as per the respective study cut-offs, BP parameters measured at least for 24 hours post procedure (mean, minimum, maximum according to the study), rates of symptomatic intracranial haemorrhage (ICH) at 24-36 hours as per the respective study definition and the 3- month mRS according to peri-procedural BP.

7

8 Risk of Bias Assessment

9 The Newcastle Ottawa Scale (NOS) was used by B.P (reviewed by P.H) to assess the risk of
10 bias in the observational studies. The Risk of Bias (ROB2) tool was used by B.P (reviewed
11 by P.H) for assessing risk of bias in randomized controlled trials.

- 12
- 13 Strategy for Data Analysis

14 Statistical analyses were performed using Review Manager 5.4.1 software by B.P and 15 reviewed by P.H. Random-effects model was used in view of expected heterogeneity to be 16 present due to known differences in stroke patient characteristics, SBP cut-offs and different 17 types of studies(observational and RCTs). The overall effect estimate, and 95% CI was used to generate Forest plots. Heterogeneity was assessed by the Higgin I^2 statistics. The primary 18 19 and all secondary efficacy and safety outcomes were assessed by risk ratios (RR). Sensitivity 20 analysis using the leave one study out analysis was done. GRADE pro GDT was used for 21 certainty of evidence assessment.

22

23 **Results**

24

25 Study selection and evaluation

An initial database search using the MeSH terms yielded 9883 records which included 8958 from PubMed, 1045 from Google Scholar, 545 from Scopus, 288 from EMBASE and 129 from Web of Science. 1026 duplicates were removed(Figure-1). 8857 studies entered the title and abstract screening of which 8713 studies were found to be irrelevant. 72 studies were assessed for full text eligibility and 60 studies were excluded(reasons in the PRISMA flowchart-Figure 1). A total of twelve studies were included in the meta-analysis.

32

33 Study Characteristics

34 Of the twelve studies involving 5439 patients included in the final analysis, eight were observational and four were RCTs.⁷⁻¹⁸ Observational study data for 3868 patients and data 35 36 from RCTs involving total of 1571 patients was also extracted separately. We used the 37 published data only for conducting the analysis. We did not have access to individual patient 38 data in any of the studies included in the meta-analysis. Five out of the eight observational studies used a SBP cut-off of 140 mmHg to define intensive control.^{11,13,15–17} Two(Chang et 39 40 al-2019 and P.Upadhyaya et al-2023) studies used a cut-off of 130 mmHg and one study(Eva.A.Mistry et al) used a cut-off of 158mmHg.^{12,14,18} In case of the RCTs the 41 ENCHANTED2/MT used a cut-off SBP of 120mmHg to define its intensive arm.⁸ The BP-42 TARGET on the other hand used a range of SBP between 100-129mmHg to define its 43 intensive arm.⁷ There were 3 SBP groups in the BEST-II(140,160,180).⁹ For combining the 44

effects we clubbed the <160mmHg and <180mmHg groups into the less intensive group and
 the <140mmHg as the intensive arm. The OPTIMAL-BP used a SBP cut-off of 140mmHg.¹⁰

3 The baseline characteristics and attributes of each study included in this meta-analysis are

4 summarised in the Table-1 and Table-2.

- 5
- 6 Risk of Bias
- 7 Observational Studies
- 8 The Newcastle Ottawa Scale results are summarised in the *Supplementary material-3*. We 9 found all studies to be of good methodological quality with a median of 8 stars.
- 10 11
- RCTs

12 The ROB2 tool demonstrated a "high risk" of bias in the deviations from the intended 13 intervention domain (Domain-2) in three out of four included RCTs. One study had 14 "some concerns" in this domain. The other domains examined had a low risk of bias. The 15 detailed analysis is provided in the *Supplement (Supplementary material-3)*.

- 16
- 17 *Outcomes*
- 18 Primary Outcome mRS 0-2

Pooled data of all the twelve studies involving 5398 patients (reported outcomes) with 2983 patients in the intensive blood pressure control group and 2415 patients in the conventional control group demonstrated that the primary outcome of mRS-0-2 was seen in 1508/2983(50.55%) patients in the intensive arm as compared to 1106/2415(45.8%) in the conventional arm and was not significantly different between both the arms(RR-1.16 ;

24 95%CI-0.98-1.37; p=0.08) as seen in Figure-2.⁷⁻¹⁸

Separate analysis of data from eight observational studies showed that mRS 0-2 was seen in
1171 out of 2235 in the intensive control group (52.39%) as compared to 674 out of 1633
patients in the conventional group (41.23%) favouring intensive blood pressure control for a
good outcome(RR-1.34; 95%CI-1.20-1.48; p<0.00001) as shown in Figure-2.¹¹⁻¹⁷

29 Similarly, a separate analysis of data from four RCTs showed that the primary outcome was

- seen in 337/748(45.05%) patients in the intensive arm as compared to 432/782(55.24%) in the conventional arm thus forward the conventional arm for a good outcome (BB 0.82).
- the conventional arm thus favouring the conventional arm for a good outcome(RR-0.82; 95%CI-0.72-0.93; p=0.003) as shown in Figure-2.⁷⁻¹⁰
- 33
- 34 Death at 90 days

Outcomes for death at 90days were available for 2985 patients in the intensive arm and 2417 patients in the conventional arm from twelve studies. A total of 487/2985(16.3%) patients died in the intensive arm as compared to 485/2417(20.06%) in the conventional arm and the difference between both the arms was not significant(RR-0.83; 95%CI-0.68-1.02; p=0.08) as shown in Figure-3.⁷⁻¹⁸

40 A separate analysis of data from eight observational studies showed that 373/2235(15.97%)

41 patients died in the intensive arm as compared to 375/1633(22.96%) in the conventional arm.

- 42 The difference between both the arms was significant with lower risk of dying in the
- 43 intensive arm(RR-0.72; 95%CI-0.59-0.87; p=0.0008) as shown in Figure-3.¹¹⁻¹⁷.

1 Data from the four RCTs showed that 114/750(15.2%) patients died in the intensive arm as

2 compared to 110/784(14.03%) patients in the conventional arm and the difference between

3 both the arms was not statistically significant (RR-1.13; 95%CI-0.88-1.44; p=0.34) as shown

- 4 in Figure-3.^{7–10}
- 5
- 6 Symptomatic ICH

Data on symptomatic ICH(sICH) was available for nine out of twelve studies involving 2385
patients in the intensive arm and 1797 patients in the conventional arm. A total of
130/2385(5.45%) patients had sICH(as per respective study definition) in the intensive arm
compared to 127/1797(7.07%) in the conventional arm and the difference between the two
groups was not statistically significant(RR-0.84; 95%CI-0.61-1.16; p=0.29) as shown in

12 Figure-4.^{7–11,13,16–18}

A separate analysis of data from five observational studies showed that sICH occurred in 74/1632(4.53%) patients in the intensive arm compared to 76/1010(7.52%) patients in the conventional arm and the risk of sICH was significantly lower in the intensive arm compared

16 to the conventional arm(RR-0.64; 95%CI-0.43-0.96; p=0.03) as shown in Figure-4.^{11,13,16–18}

17 Data from the four RCTs showed that symptomatic ICH occurred in 56/753(7.44%) patients

in the intensive arm compared to 51/787(6.48%) patients in the conventional arm with no

significant differences between the two groups(RR-1.13; 95%CI-0.78-1.63; p=0.52) as shown
 in Figure-4.⁷⁻¹⁰

21

22 Decompressive surgery

Data on decompressive surgery was available from four out of twelve studies for 1684 patients in the intensive arm as compared to 959 patients in the conventional arm. A total of 44/1684(2.61%) patients in the intensive arm required decompression as compared to 54/959(5.63%) patients in the conventional arm. There was significantly higher requirement of decompressive surgery in the conventional management arm compared to the intensive arm (RR-0.40; 95%CI-0.25-0.66; p=0.0003) as shown in Figure-5.^{7,13,16,18}

A separate analysis of only observational study data from three studies showed that 43/1526

- 30 (2.82%) patients required decompressive surgery in the intensive arm compared to 54/797
- 31 (6.76%) patients in the conventional arm with the chances of needing a decompression higher
- in the conventional arm than intensive arm(RR-0.39; 95%CI-0.25-0.59; p<0.00001) as shown
- 33 in Figure-5.^{13,18,19}
- 34

35 Optimal Systolic Blood Pressure cut-offs

We further explored the various SBP cut-offs (SBP at which anti-hypertensive medications would be started and the target SBP up to 24hours after EVT) used across the studies and segregated them into groups of studies using a cut-off of 140mmHg to define intensive control and 130mmHg to define intensive control.

40

41 Primary outcome for a SBP cut-off of 140mmHg

42 Pooled analysis of seven studies(n=2156 patients in intensive arm and 1488 patients in

- 43 conventional arm) for the primary outcome of mRS 0-2 at 90days with a cut-off of 140mmHg
- to define intensive control did not show in any significant differences between the intensive

1 or less intensive/conventional control(RR-1.14; 95%CI-0.96-1.36; p=0.14) as shown in the

2 Figure-6.^{9–11,13,15–17}

3 However a separate analysis of five observational studies (n=1964 patients in the intensive

- 4 arm and 1265 patients in conventional arm) only using the 140mmHg cut-off for the primary
- 5 outcome demonstrated a significant chance of favourable outcome in the intensive arm(RR-
- 6 1.26; 95% CI-1.13-1.40; p<0.0001) as shown in Figure-6.^{11,13,15-17}
- 7 A similar analysis for two RCTs (n=192 patients in intensive arm and 223 patients in the
- 8 conventional arm) with the SBP cut-off of 140mmHg did not show a significant difference
- 9 between the two groups (RR-0.79; 95% CI-0.61-1.04; p=0.09) as shown in Figure-6.^{9,10}
- 10 Among the other outcomes death at 90days was significantly lower in the intensive control
- 11 arm in the observational data involving five studies (n=1964 in intensive arm and n=1265 in 12 H_{n} (DP 0.75, 0.52) (CL 0.60.07, 0.02)
- 12 conventional arm) with the cut-off of 140mmHg(RR-0.76; 95%CI-0.60-0.97; p=0.03) as
- 13 shown in Supplemental Figure-2. The details about the other outcomes of sICH,
- decompressive surgery at different cut-offs can be found in the *Supplemental material-4 Figures-1,2,3*.
- 16

17 Primary outcome for a SBP cut-off of 130mmHg

18 An analysis of three studies (n=244 in intensive arm and n=254 in conventional arm) with

- 19 respect to the primary outcome using a target SBP cut-off of 130mmHg did not show any
- significant differences between the two groups(RR-1.27; 95%CI-0.92-1.74; p=0.15) as shown
 in Figure-6.^{7,14,18}
- 22 The details about the other outcomes of sICH and decompressive surgery and different cut-
- 23 offs can be found in the *Supplemental material-4; Figures-1,2,3*.
- We could not explore other lower(one study) and higher cut-offs(two studies) due to limited number of studies in these groups and non-availability of individual patient data.
- 26
- 27 Leave-out-one study Influence analysis
- 28 Leaving out the ENCHANTED-2/MT and OPTIMAL-BP results resulted in a change in the 29 outcome of the pooled data such that the intensive arm had a higher odds of having a better functional outcome as compared to conventional BP management.^{8,10} Leave out one study 30 31 analysis did not lead to any change in the primary outcome in a separate analysis of only 32 observational studies. Similar to the combined analysis, leaving out the ENCHANTED-2/MT 33 and OPTIMAL-BP results resulted in a change in the outcome of the RCT pooled data but the difference was such that neither arm was preferred^{8,10}. Leaving out the other two RCTs did 34 not change outcomes. The details are provided in the supplement (Supplementary material-35 36 5).
- 37
- 38 GRADE

The GRADEpro GDT (<u>https://www.gradepro.org</u>) was used to assess the certainty of evidence and was found to be moderate to low in case of observational studies and moderate in case of the RCTs. The summary of the GRADE findings is presented in the *Supplementary material-6*.

- 43
- 44 Discussion

1 Our systematic review and meta-analysis involving eight observational studies and four 2 RCTs analysed the effects of an intensive as compared to a conventional/less intensive blood 3 pressure control up to 24 hours of thrombectomy in all strokes (eleven studies on anterior 4 circulation and one on posterior circulation stroke). The results suggest that neither intensive 5 nor conventional management of blood pressure post thrombectomy resulted in any 6 difference in the functional outcomes i.e. mRS-0-2 at 90days. Similarly the risk of death and 7 sICH were also similar in both groups. A significantly fewer patients required decompressive 8 surgery in the intensive arm as compared to the conventional arm. Separate analysis of data 9 from observational studies and data from RCTs revealed discordant results. The primary 10 outcome i.e. achieving a mRS 0-2 at 90 days was higher in the intensive arm as compared to 11 the conventional arm in observational studies whereas the conventional management was 12 favoured from RCT data. Mortality at 90 days was also lower in the intensive arm as 13 compared to the conventional arm in the observational data and both groups were comparable 14 as per pooled data from the RCTs. Similarly the observational data favoured intensive control 15 with lower rates of symptomatic ICH as compared to a conventional blood pressure control. 16 The pooled data of the RCTs did not favour any particular arm. Decompressive surgery was 17 more likely to be required in the conventional arm as compared to the intensive arm.

18

19 The optimal blood pressure after endovascular therapy has remained elusive ever since the 20 procedure was introduced. Numerous hypotheses have been suggested favouring and 21 negating intensive and conventional management. Arguments in favour of intensive 22 management primarily derived from observational studies and stemmed from the fact that 23 intensive control reduced the rates of symptomatic ICH, reduced cerebral hyper perfusion thereby reducing cerebral edema and improving outcomes.^{13,19} However with the robust 24 RCTs like the ENCHANTED-2/BP-TARGET not favouring the intensive arm an alternate 25 school of thought has emerged.^{7,8} Firstly, higher SBP might be associated with maintenance 26 of perfusion to distal branches of the blood vessel after successful recanalization. A more 27 28 intensive SBP control would lead to focal areas of hypoperfusion leading to infarct 29 progression and poor outcomes. Secondly, a successful recanalization after EVT may have 30 persistent venous postcapillary thrombosis and an intensive BP reduction could be 31 detrimental and further promote infarct and ischemia progression.²⁰

32

Blood pressure is a dynamic entity subject to cerebral autoregulation which in turn is unique to a patient. Blood pressure variability post EVT have also been observed to be associated with poor outcomes.²¹ It is therefore important to avoid wide fluctuations in the blood pressure.

37

The pooled data did not show any difference in outcomes with the type of BP management strategy used although there was a trend towards better outcomes in the intensive arm which could be due to the reduced risk of reperfusion injury and lower risk of haemorrhagic transformation.^{11,16} The requirement of decompressive surgery was also significantly lower in the intensive arm. This could also be explained by the fact that lower SBP probably reduced the risk of reperfusion injury and subsequent infarct expansion and cerebral edema.¹⁶ The separate analysis of observational and RCT data showed discordant results. This discordance

1 in the observational and randomised data could be attributed to multiple factors. First, 2 randomised trials are conducted in a controlled environment with strict BP targets and had 3 patients for longer periods of time in the intended target. The higher rates of hypotensive 4 events in the intensive group patients in the RCTs might have been a potential confounder for 5 the poor outcomes in this group. On the other hand the BP in observational studies is more 6 like the real world with some studies using the peak SBP and some using the mean SBP over 7 a period of 24 hrs after the procedure. Since BP fluctuates throughout the day and the mean 8 BP is unlikely to reflect these wide fluctuations and it is difficult to ascertain whether these so 9 called 'intensive' arm patients were actually intensively treated.

10

Second, RCTs used drugs to both increase and decrease the blood pressure to set targets and it is possible that these drugs could have been a potential confounder with respect to unknown pleotropic effects of the anti-hypertensive drug.⁸ Such data was not available for all the observational studies.

15

16 Third, although the observational studies selected had a net low risk of bias (using the NOS tool) it is not possible to completely eliminate selection and observer's bias inherent in all observational studies.

19

Fourth, the observational cut-offs used were different for different studies. We used the definition of intensive as defined by the study which is the reason for the significant heterogeneity. A total of five out of eight observational studies namely Goyal et al, Anadani et al(2019), Cernik et al, Anadani et al (2020) and Han et al used a SBP cut off of 140mmHg as a definition for intensive control.^{13,15,17,19,22} On the other hand 2 studies by Chang et al and P Upadhyay et al used a lower cut-off of 130mmHg.¹⁴ A SBP cut-off of 158mmHg was found to dichotomise functional outcomes in the Mistry et al (2019) study.¹²

27 The cut-offs used in the RCTs for defining intensive was also different across studies with the 28 ENCHANTED-2/MT and BP-TARGET defining the upper limit of SBP for the intensive arm at 120mmHg and the BEST-II dividing the BP into three groups of 140,160 and 180 and the 29 OPTIMAL-BP using a upper limit SBP of 140mmHg.⁷⁻⁹ Even though we did a separate 30 31 analysis using different cut-offs of 140mmHg and 130mmHg to define the intensive arm 32 there was no difference in the results as the observational data favoured the intensive arm. 33 The difference was seen in the RCT data as removing ENCHANTED-2/MT and BP-TARGET trials resulted in no significant difference in the two arms.^{7,8} A lower cut off of 34 130mmHg also did not result in any significant differences between the arms. Access to 35 36 individual patient data of these studies could have allowed us to study higher BP targets to 37 identify the SBP sweet spot across studies by pooling the blood pressure recordings and 38 subsequently dichotomising the outcomes.

39

40 Another important aspect to note is the heterogeneity in perfusion deficit of the patients 41 recruited in the study. In the RCT data the ENCHANTED2/MT had reported a considerable 42 number of patients with a significant perfusion deficit before the thrombectomy and such 43 cases are extremely prone to reinfarction and infarct progression if the blood pressure is 44 lowered.⁸

1

Further studies involving more patients and more uniform BP cut-offs will provide better answers in the future. The findings of our study based on RCT data which are considered Level-1 evidence favour a conventional management of blood pressure with target SBP of 140-180mmHg in line with the recommendations from the AHA/ASA.

- 6
- 7

9

8 Strengths

10 The major strengths of this meta-analysis is the comprehensive search methodology and an 11 inclusive study pooling data of all the published studies till date. It also includes data of one 12 study with posterior circulation strokes.

- 13
- 14

15 Limitations

16

The major limitation of this study is that it uses only data that was reported. A study with individual patient data could have led to better identification of the true cut-off SBP for achieving a good outcome and we could have explored higher targets in better detail. We also could not explore posterior circulation strokes separately as there was only one study exploring this.¹⁷ We could have performed meta-regression by adjusting for co-variates to predict whether age, recanalization grade or the admission blood pressure had an effect on the final outcome.

24

25

26 Conclusion

27 Results of this meta-analysis suggest that combined data from all studies does not favour 28 either intensive or conventional SBP control after EVT. Observational data showed intensive 29 control to be associated with higher chances of functional recovery, reduced mortality and 30 risk of symptomatic ICH. Data from RCTs showed conventional SBP control to be associated 31 with improved functional outcomes but no effect on mortality suggesting conventional 32 management as the preferred pragmatic approach. Further ongoing RCTs using homogenous 33 SBP cut-offs will provide more clarity on the ideal SBP target after EVT.

- 34
- 35
- 36
- 37
- 38 39
- 40
- 41
- 42
- 43
- 44

- 1
- 2
- 3
- 4
- 5
- 5 6
- 7 Acknowledgements
- 8 Nil
- 9 Funding
- 10 Nil
- 11 Disclosures and Conflicts of Interest
- 12 B.P, R.B, P.H, R.S and I.L report no disclosures and no conflicts of interest.
- 13 Consent
- 14 Not required as this is a systematic review and meta-analysis.
- 15 Ethical Statement
- 16 No ethical clearance was required as this is a systematic review and meta-analysis
- 17 Contributions
- 18 Baikuntha Panigrahi: Drafting/revision of the manuscript for content, including medical
- 19 writing for content; Major role in the acquisition of data; Study concept or design; Analysis
- 20 or interpretation of data. Rohit Bhatia: Drafting/revision of the manuscript for content,
- 21 including medical writing for content; Major role in the acquisition of data; Study concept or
- 22 design; Analysis or interpretation of data. Partha Haldar: Drafting/revision of the manuscript
- 23 for content, including medical writing for content; Analysis or interpretation of data. Risha
- 24 Sarkar: Major role in the acquisition of data. Imnameren Longkumer: Major role in the
- 25 acquisition of data.
- 26

27 Supplemental Material(S)

- 28 **S1-**PRISMA checklist
- 29 S2-Review Question and PICO Statements
- 30 **S3**-Risk of Bias analysis
- 31 S4- Outcomes analysed using different SBP cut-offs
- 32 **S5**-Leave one study out analysis
- **S6**-GRADE assessment of certainty of evidence
- 34 Supplemental Figures-S3
- 35
- 36
- 37
- 38
- 39 40

1 2 3 4 5 6 7 8 9 10 11 12	Re f 1.	ferences Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke</i> . 2019;50(12):e344-
13 14 15 16	2.	e418. doi:10.1161/STR.000000000000211 Rabinstein AA, Albers GW, Brinjikji W, Koch S. Factors that may contribute to poor outcome despite good reperfusion after acute endovascular stroke therapy. <i>International</i> <i>Journal of Stroke</i> . 2019;14(1):23-31. doi:10.1177/1747493018799979
17 18 19	3.	Katsanos AH, Malhotra K, Ahmed N, et al. Blood pressure after endovascular thrombectomy and outcomes in patients with acute ischemic stroke: An individual patient data meta-analysis. <i>Neurology</i> . 2022;98(3):e291-e301.
20 21	4.	Hong L, Cheng X, Lin L, et al. The blood pressure paradox in acute ischemic stroke. <i>Ann Neurol.</i> 2019;85(3):331-339.
22 23 24	5.	Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. <i>N Engl J Med</i> . 2015;372(11):1019-1030. doi:10.1056/NEJMoa1414905
25 26 27	6.	Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. <i>N Engl J Med</i> . 2018;378(1):11-21. doi:10.1056/NEJMoa1706442
28 29 30 31	7.	Mazighi M, Richard S, Lapergue B, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. <i>Lancet Neurol</i> . 2021;20(4):265-274. doi:10.1016/S1474-4422(20)30483-X
32 33 34 35	8.	Yang P, Song L, Zhang Y, et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. <i>Lancet</i> . 2022;400(10363):1585-1596. doi:10.1016/S0140-6736(22)01882-7
36 37 38	9.	Mistry EA, Hart KW, Davis LT, et al. Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial. <i>JAMA</i> . 2023;330(9):821. doi:10.1001/jama.2023.14330
39 40 41	10.	Nam HS, Kim YD, Heo J, et al. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke: The OPTIMAL-BP randomized clinical trial. <i>JAMA</i> . 2023;330(9):832-842.

1 2 3	11.	Goyal N, Tsivgoulis G, Pandhi A, et al. Blood pressure levels post mechanical thrombectomy and outcomes in large vessel occlusion strokes. <i>Neurology</i> . 2017;89(6):540-547. doi:10.1212/WNL.00000000004184
4 5 6 7 8 9	12.	Mistry EA, Sucharew H, Mistry AM, et al. Blood pressure after endovascular stroke therapy (BEST): Final results of a prospective multicenter cohort validation study. <i>Stroke</i> . 2019;50((Mistry E.A.; Sucharew H.; Mistry A.M.; Mehta T.; Arora N.; De Los Rios La Rosa F.; Starosciak A.K.; EI James S.; Barnhill N.R.; Patel K.; Assad S.; Tarboosh A.T.; Dakay K.; Cruz A.; Wagner J.; Fortuny E.; Bennett A.; James R.; Jagadeesan B.; Streib C.; O). doi:10.1161/str.50.suppl_1.94
10 11	13.	Anadani M, Orabi MY, Alawieh A, et al. Blood pressure and outcome after mechanical thrombectomy with successful revascularization. <i>Stroke</i> . 2019;50(9):2448-2454.
12 13	14.	Chang JY, Han MK. Postthrombectomy systolic blood pressure and clinical outcome among patients with successful recanalization. <i>Eur Neurol.</i> 2019;81(5-6):216-222.
14 15 16 17	15.	Cernik D, Sanak D, Divisova P, et al. Impact of blood pressure levels within first 24 hours after mechanical thrombectomy on clinical outcome in acute ischemic stroke patients. <i>Journal of NeuroInterventional Surgery</i> . 2019;11(8):735-739. doi:10.1136/neurintsurg-2018-014548
18 19 20	16.	Anadani M, Arthur AS, Tsivgoulis G, et al. Blood Pressure Goals and Clinical Outcomes after Successful Endovascular Therapy: A Multicenter Study. <i>Annals of Neurology</i> . 2020;87(6):830-839. doi:10.1002/ana.25716
21 22 23	17.	Han B, Sun X, Liu R, et al. Impact of the perioperative blood pressure on clinical outcome after thrombectomy in acute basilar artery occlusion. <i>J Stroke Cerebrovasc Dis</i> . 2021;30(3):105590.
24 25 26	18.	Upadhyaya P, Mehta A, Luby M, et al. Good outcome associated with blood-brain barrier disruption and lower blood pressure after endovascular therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> . 2023;32(1). doi:10.1016/j.jstrokecerebrovasdis.2022.106870
27 28 29	19.	Anadani M, Arthur AS, Alawieh A, et al. Blood pressure reduction and outcome after endovascular therapy with successful reperfusion: a multicenter study. <i>J Neurointerv Surg.</i> 2020;12(10):932-936.
30 31 32 33	20.	Deng G, Chu YH, Xiao J, et al. Risk Factors, Pathophysiologic Mechanisms, and Potential Treatment Strategies of Futile Recanalization after Endovascular Therapy in Acute Ischemic Stroke. <i>Aging Dis.</i> 2023;14(6):2096-2112. doi:10.14336/AD.2023.0321- 1
34 35 36	21.	Nepal G, Shrestha GS, Shing YK, Muha A, Bhagat R. Systolic blood pressure variability following endovascular thrombectomy and clinical outcome in acute ischemic stroke: A meta analysis. <i>Acta Neurol Scand</i> . 2021;144(4):343-354. doi:10.1111/ane.13480
37 38 39	22.	Goyal N, Tsivgoulis G, Iftikhar S, et al. Admission systolic blood pressure and outcomes in large vessel occlusion strokes treated with endovascular treatment. <i>Journal of</i> <i>NeuroInterventional Surgery</i> . 2017;9(5):451-454. doi:10.1136/neurintsurg-2016-012386
40		

Table-1-Baseline characteristics of the study population of RCTs

Total number of participants randomised 324 821 120 306 Number of patients in Intensive Arm (ITT) 158 407 40 155 Number of patients in less intensive arm (ITT) 158 409 80 150 (ITT) Age {Mean} Intensive Arm 68 73.2 50 324 821 12 12.1 Age {Mean} Intensive Arm 67 72.9 50 306 73.2 SD Age in Intensive Arm 67 72.9 50 308 10.8 Age {Meain} Less Intensive Arm 12 10.8 306 308 Age {Median} Intensive Arm 66-85 66.8-84.8 409	Characteristic	Mazighi 2021 ⁷	Yang 2022 ⁸	Mistry 2023 ⁹	Nam 2023 ¹⁰
Number of patients in Intensive Arm (ITT) 158 407 40 155 Number of patients in less intensive arm (ITT) 162 409 80 150 Age {Mean} Intensive Arm 68 73.2 50 73.2 50 72.9 50 72.9 50 72.9 50 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 74 10.8 75 74 10.8 75 74 10.8	Total number of participants randomised	324	821	120	306
Number of patients in less intensive arm (ITT) 162 409 80 150 Age (Mean) Intensive Arm 68 73.2 SD Age in Intensive Arm 12 12.1 Age (Mean) Less Intensive Arm 67 72.9 SD Age in Less Intensive Arm 12 10.8 Age (Median) Intensive Arm 12 10.8 Age (Median) Intensive arm 77 74 IQR Age Intensive Arm 66-85 66.8-84.8 Age (Median-Less Intensive) 76 12 IQR Age Less Intensive Arm 62-82 12 Males n; Intensive Arm 81 249 12 92 % Males ni Intensive Arm 51 61 30 59.4 Males n;Less Intensive Arm 72 257 39 88 Males n;Less Intensive Arm 110 267 32 121 Hypertension n; Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm <td>Number of patients in Intensive Arm (ITT)</td> <td>158</td> <td>407</td> <td>40</td> <td>155</td>	Number of patients in Intensive Arm (ITT)	158	407	40	155
Age {Mean} Intensive Arm 68 73.2 SD Age in Intensive Arm 12 12.1 Age {Mean} Less Intensive Arm 67 72.9 SD Age in Less Intensive Arm 12 10.8 Age {Median} Intensive arm 12 10.8 Age {Median} Intensive arm 77 74 IQR Age Intensive Arm 66-85 66.8-84.8 Age{Median-Less Intensive} 76 12 IQR Age Less Intensive Arm 62-82 12 Males n; Intensive Arm 51 61 30 Males n; Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension n; Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm<	Number of patients in less intensive arm (ITT)	162	409	80	150
SD Age in Intensive Arm 12 12.1 Age {Mean} Less Intensive Arm 67 72.9 SD Age in Less Intensive Arm 12 10.8 Age {Median} Intensive arm 77 74 IQR Age Intensive Arm 66-85 66.8-84.8 Age {Median-Less Intensive} 76 76 IQR Age Less Intensive Arm 62-82 92 Males n; Intensive Arm 51 61 30 59.4 Males n; Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension n; Less Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	Age {Mean} Intensive Arm		68		73.2
Age {Mean} Less Intensive Arm 67 72.9 SD Age in Less Intensive Arm 12 10.8 Age {Median} Intensive arm 77 74 IQR Age Intensive Arm 66-85 66.8-84.8 Age {Median-Less Intensive } 76 10 IQR Age Less Intensive Arm 62-82 10 Males n; Intensive Arm 81 249 12 92 % Males in Intensive Arm 51 61 30 59.4 Males n;Less Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	SD Age in Intensive Arm		12		12.1
SD Age in Less Intensive Arm 12 10.8 Age { Median } Intensive arm 77 74 IQR Age Intensive Arm 66-85 66.8-84.8 Age{Median-Less Intensive } 76 66.8-84.8 IQR Age Less Intensive Arm 62-82 61 Males n; Intensive Arm 51 61 30 % Males in Intensive Arm 72 257 39 88 Males n;Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension n; Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8	Age {Mean} Less Intensive Arm		67		72.9
Age {Median} Intensive arm 77 74 1000000000000000000000000000000000000	SD Age in Less Intensive Arm		12		10.8
IQR Age Intensive Arm66-8566.8-84.8Age{Median-Less Intensive}76IQR Age Less Intensive Arm62-82Males n; Intensive Arm812491292% Males in Intensive Arm5161303059.4Males n;Less Intensive Arm722573988Males(%) in Less Intensive Arm456348.7599Hypertension n; Intensive Arm11026732110Hypertension n; Less Intensive Arm11326160110Hypertension % Less Intensive Arm71647574.8Smoker n: Intensive Arm19	Age {Median} Intensive arm	77		74	
Age{Median-Less Intensive}76Image: Constraint of the systemIQR Age Less Intensive Arm62-82Image: Constraint of the systemMales n; Intensive Arm8124912% Males in Intensive Arm516130Males n;Less Intensive Arm7225739Males(%) in Less Intensive Arm456348.75Hypertension n; Intensive Arm11026732Hypertension(%) Intensive Arm706680Hypertension n; Less Intensive Arm11326160Hypertension % Less Intensive Arm716475Smoker n: Intensive Arm19839	IQR Age Intensive Arm	66-85		66.8-84.8	
IQR Age Less Intensive Arm 62-82 Image: constraint of the system of	Age{Median-Less Intensive}	76			
Males n; Intensive Arm 81 249 12 92 % Males in Intensive Arm 51 61 30 59.4 Males n;Less Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension(%) Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	IQR Age Less Intensive Arm	62-82			
% Males in Intensive Arm 51 61 30 59.4 Males n;Less Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension(%) Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	Males n; Intensive Arm	81	249	12	92
Males n;Less Intensive Arm 72 257 39 88 Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension(%) Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	% Males in Intensive Arm	51	61	30	59.4
Males(%) in Less Intensive Arm 45 63 48.75 59.9 Hypertension n; Intensive Arm 110 267 32 121 Hypertension(%) Intensive Arm 70 66 80 78.1 Hypertension n; Less Intensive Arm 113 261 60 110 Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	Males n;Less Intensive Arm	72	257	39	88
Hypertension n; Intensive Arm11026732121Hypertension(%) Intensive Arm70668078.1Hypertension n; Less Intensive Arm11326160110Hypertension % Less Intensive Arm71647574.8Smoker n: Intensive Arm19839	Males(%) in Less Intensive Arm	45	63	48.75	59.9
Hypertension(%) Intensive Arm70668078.1Hypertension n; Less Intensive Arm11326160110Hypertension % Less Intensive Arm71647574.8Smoker n: Intensive Arm19839	Hypertension n; Intensive Arm	110	267	32	121
Hypertension n; Less Intensive Arm11326160110Hypertension % Less Intensive Arm71647574.8Smoker n: Intensive Arm19839	Hypertension(%) Intensive Arm	70	66	80	78.1
Hypertension % Less Intensive Arm 71 64 75 74.8 Smoker n: Intensive Arm 19 8 39	Hypertension n; Less Intensive Arm	113	261	60	110
Smoker n: Intensive Arm 19 8 39	Hypertension % Less Intensive Arm	71	64	75	74.8
	Smoker n; Intensive Arm	19		8	39
Smokers(%) Intensive Arm142025.2	Smokers(%) Intensive Arm	14		20	25.2
Smoker n; Less Intensive Arm242229	Smoker n; Less Intensive Arm	24		22	29
Smoker % Less Intensive Arm1627.519.7	Smoker % Less Intensive Arm	16		27.5	19.7
Diabetes n; Intensive Arm34811265	Diabetes n; Intensive Arm	34	81	12	65
Diabetes(%) Intensive Arm 22 20 30 41.9	Diabetes(%) Intensive Arm	22	20	30	41.9
Diabetes n; Less Intensive Arm33822862	Diabetes n; Less Intensive Arm	33	82	28	62
Diabetes % Less intensive Arm21203542.2	Diabetes % Less intensive Arm	21	20	35	42.2
Atrial Fibrillation n Intensive Arm841977	Atrial Fibrillation n Intensive Arm		84	19	77
Atrial Fibrillation(%) Intensive Arm 21 47.5 49.7	Atrial Fibrillation(%) Intensive Arm		21	47.5	49.7
Atrial Fibrillation n; Less Intensive Arm983469	Atrial Fibrillation n; Less Intensive Arm		98	34	69
Atrial Fibrillation(%) Less Intensive Arm 24 42.5 46.9	Atrial Fibrillation(%) Less Intensive Arm		24	42.5	46.9
Prior Stroke history n; Intensive Arm2510736	Prior Stroke history n; Intensive Arm	25	107		36
Prior Stroke History(%) Intensive Arm 16 26 23.2	Prior Stroke History(%) Intensive Arm	16	26		23.2

Prior Stroke history; n Less Intensive Arm	21	139		30
Prior Stroke % Less Intensive Arm	13	34		20.4
Median NIHSS at presentation Intensive Arm	18	15	16	13
Median NIHSS at presentation Less	17	15	18^(160)+14^(180)	12
Site M1 MCA n; Intensive Arm	117		31	
%M1 MCA-Intensive	74		77.5	
M1 MCA n; Less Intensive Arm	119		48	
M1 MCA (%) Less Intensive Arm	75		60	
ICA n; Intensive Arm			7	
ICA % Intensive Arm			17.5	
ICA n; Less Intensive Arm			14	
ICA (%) Less Intensive Arm			17.5	
IV Thrombolysis use n; Intensive Arm	85	132	17	44
IV Thrombolysis use %; Intensive Arm	54	32	42.5	28.4
IV Thrombolysis use n; Less Intensive	83	115	37	54
IV Thrombolysis use (%) Less Intensive Arm	52	28	46.25	36.7
Mean SBP at presentation Intensive Arm	155	158.1	150	
SD SBP- Intensive Arm	26	25	22.5	
Mean SBP at presentation; Less Intensive	152	158.7	151^/146^(160/180)	
SD SBP-Less Intensive Arm	25	23	25.3^(160)/23^(180)	
Mean DBP at presentation-Intensive Arm	86	89.4	82.6	
SD DBP-Intensive Arm	18	16	14.5	
Mean DBP at presentation-Less Intensive	85	89.5	89^(160)/86.6^(180)	
SD DBP-Less Intensive Arm	15	15	18.4^(160)/19.6^(180)	
Onset to Puncture time in minutes-				388
Intensive Arm Onset to Puncture time in minutes-Less				357
intensive Arm Onset to recanalization time in minutes-	285			421
Intensive	207			200
Less Intensive	237			377
Arm	56		45	
Recanalization mTICI 3 (%) Less Intensive Arm	52		42.5	
Recanalization mTICI 2b (%) Intensive	44		40	
Recanalization mTICI 2b (%) Less Intensive Arm	48		42.5	
Mean procedure Time in minutes - Intensive Arm		54		30
Mean procedure Time in minutes-Less		60		31
Last Known well in minutes (SD)		558	238	
Intensive Arm Last Known well in minutes (SD) Less		516	222	
Intensive Arm	dividual group i	n brackata		

Table-2-Baseline characteristics of the study population of Observational Studies

Characteristic	Goyal et al ¹¹	Eva A. Mistry et al ¹²	Anadani et al ¹³	Chang et al ¹⁴	Cernik D et al ¹⁵	Anadani et al ¹⁶	Han et al ¹⁷	P. Upadhyaya et al ¹⁸ .
Year	2017	2019	2019	2019	2019	2020	2021	2023
BP Cut-offs	140	158	140	130	140	140	140	130
No of patients-total	217	485	1245	90	690	1019	187	103
n-Intensive	10	195	942	48	376	540	96	44
n-Less intensive	130	290	259	42	314	479	83	59
Age(Mean)-Total	62		69	72.3	71		60	
Age(SD)-Total	14		14	11.8	13		10	
Age(Mean)_intensive	61.2 <u>+</u> 14.2			70.1		70		
Age(Mean)-Less Intensive				74.9				
Age(Median)		69						66
Age(IQR)		57-79						57-75
Males(n)	108	236	614	54	352	508	157	40
Males(%)	50	48.66	49.3	60	51	49.8	84	38.8
Males(Intensive)-n	2			31		259		18
% males-Intensive	20			64.6		47.96		40.9
Males(Less Intensive)-n	68			23		249		22
%males(Less Intensive)	52.3			54.8		51.98		37.3
Admission NIHSS-Baseline- Total	16(12- 21)	16(11-20)	16(IQR-7)	14.7 <u>+</u> 5.5	17		22(10- 34)	19
Admission NIHSS-Intensive	17	15		14.2±5.3		15		20
Admission NIHSS-Less Intensive*		17		15.3±5.8		17*(160) 16*(180)		19
Hypertension-Total-n	166	364	797	43	525	644	133	63
Hypertension%-Total	77	75	64	49.4	76	62.59	71.1	61
Hypertension-Intensive(n)	6	122		20		326		29
Hypertension(%)-Intensive	60	62.5		43.5		60		66
Hypertension-Less Intensive-n	100	242		23		318		34
Hypertension(%)-Less Intensive	76.9	83.4		56.1		66.4		59
Diabetes(Total)-n	70	139	406	25	188	356	51	17
Diabetes(Total)-%	32	29	33	28.7	27	34.94	27.3	17
Diabetes(Intensive)-n	3	51		12		192		7
Diabetes(Intensive)%	30	26		26.1		36		16
Diabetes(Less Intensive)-n	44	88		13		164		10
Diabetes(Less Intensive%)	33.8	30		31.7		34.2		18

Afib-Total-n	54	176	462	51	299			31
Afib-Total(%)	25	36	37	58	43			30
Afib(Intensive)-n	4	63		29		186		14
Afib(Intensive(%)	40	32		61.7		34.4		33
Afib(Less Intensive)-n	29	113		22		203		17
Afib(Less Intensive(%)	22.3	39		53.7		42.4		30
Prior Stroke-Total(n)							37	13
Prior Stroke-Total%							19.8	13
Prior Stroke-Intensive(n)								6
Prior Stroke-Intensive%								14
Prior Stroke-Less Intensive(n)								7
Prior Stroke-Less Intensive%								12
IVtPA-Total(n)	141	231	590	54	519	566	36	62
IVtPA-Total(%)	65	48	55	60	75	55.5	19.3	60
IVtPA-Intensive(n)	9	107		29		278		27
IVtPA-Intensive(%)	90	55		60.4		51		61
IVtPA-Less Intensive	84	124		25		288		35
IV tPA-Less intensive%	64.6	42		59.5		60		59
ICA-Total(n)	33	129	172	26	160	150		16
ICA-Total(%)	15	27	14.2	28.9	23	14.7		16
ICA-Intensive(n)		49		11		66		8
ICA-Intensive%		25		22.9		11		18
ICA-Less Intensive-n		80		15		84		8
ICA-Less Intensive(%)		27		35.7		17.5		14
MCA-M1-Total(n)	104	309	714	64	567	564		42
MCA-M1-Total(%)	48	64	57	71.1	82	55.35		41
M1-Intensive-n		108		37		315		19
M1 Intensive%		55.3		77.1		59		43
M1 Less Intensive(n)		148		27		249		23
M1 Less Intensive(%)		51		64.3		51.98		39
Post Circulation-Total-n	38						187	
Post Circulation-%	18						100	
*No of patients with e	each inc	lividual g	roup in bra	ackets	1	L		1



- Figure-1-PRISMA flowchart of the study
- 5 6
- 7
- 8

Combined Analysis(n=12)

-	Intensive Manag	ement	Conventional Manage	ment		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M–H, Random, 95% CI		
Goyal et al 2017	7	10	67	130	6.2%	1.36 [0.88, 2.11]	2017			
Anadani et al 2019	485	942	92	259	9.7%	1.45 [1.22, 1.73]	2019	+		
Cernik D et al 2019	202	376	132	314	9.9%	1.28 [1.09, 1.50]	2019	-		
Chang et al 2019	32	48	17	42	6.4%	1.65 [1.08, 2.50]	2019			
Eva A. Mistry et al 2019	96	179	90	267	9.2%	1.59 [1.28, 1.98]	2019	-		
Anadani et al 2020	283	540	222	479	10.3%	1.13 [1.00, 1.28]	2020	+		
Han et al 2021	38	96	27	83	6.7%	1.22 [0.82, 1.81]	2021			
Mazighi et al 2021	67	152	69	153	8.8%	0.98 [0.76, 1.26]	2021	+		
Yang et al 2022	192	404	247	406	10.3%	0.78 [0.69, 0.89]	2022	+		
P. Upadhyaya et al 2023	28	44	27	59	7.3%	1.39 [0.97, 1.99]	2023			
Mistry et al 2023	17	37	36	76	6.4%	0.97 [0.64, 1.48]	2023			
Nam et al 2023	61	155	80	147	8.8%	0.72 [0.57, 0.92]	2023	-		
Total (95% CI)		2983		2415	100.0%	1.16 [0.98, 1.37]		◆		
Total events	1508		1106							
Heterogeneity: Tau ² = 0.0	< 0.00001); I ² = 84%									
Test for overall effect: Z =						Eavours [conventional] Eavours [intensive]				
								ratours [contentional] Tavours [intensive]		

Observational Studies(n=8)

	Intensive C	ontrol	Conventional C	ontrol		Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl		
Goyal et al 2017	7	10	67	130	4.9%	1.36 [0.88, 2.11]	2017	+		
Eva A. Mistry et al 2019	96	179	90	267	14.4%	1.59 [1.28, 1.98]	2019	-		
Anadani et al 2019	485	942	92	259	18.2%	1.45 [1.22, 1.73]	2019	+		
Cernik D et al 2019	202	376	132	314	19.9%	1.28 [1.09, 1.50]	2019	+		
Chang et al 2019	32	48	17	42	5.4%	1.65 [1.08, 2.50]	2019			
Anadani et al 2020	283	540	222	479	24.3%	1.13 [1.00, 1.28]	2020	-		
Han et al 2021	38	96	27	83	5.9%	1.22 [0.82, 1.81]	2021	+		
P. Upadhyaya et al 2023	28	44	27	59	7.0%	1.39 [0.97, 1.99]	2023			
Total (95% CI)		2235		1633	100.0%	1.34 [1.20, 1.48]		♦		
Total events	1171		674							
Heterogeneity: $Tau^2 = 0.0$	1; Chi ² = 11.1	l6, df =	7 (P = 0.13); $I^2 =$	37%						
Test for overall effect: Z =	0001)						Favours Conventional Favours Intensive			

RCTs(n=4)

	Intensive Control		Conventional C	Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Mazighi et al 2021	67	152	69	153	20.9%	0.98 [0.76, 1.26]	2021	. -+
Yang et al 2022	192	404	247	406	48.9%	0.78 [0.69, 0.89]	2022	
Nam et al 2023	61	155	80	147	21.6%	0.72 [0.57, 0.92]	2023	
Mistry et al 2023	17	37	36	76	8.6%	0.97 [0.64, 1.48]	2023	
Total (95% CI)		748		782	100.0%	0.82 [0.72, 0.93]		•
Total events	337		432					
Heterogeneity: Tau ² =	= 0.00; Chi ² =	4.00, d	f = 3 (P = 0.26);	$I^2 = 25\%$				
Test for overall effect:	Z = 2.99 (P =	= 0.003))					Favours Conventional Favours Intensive

Figure-2-Forest plot for the primary outcome of mRS 0-2 at 90 days.

Legend- The estimated risk ratio-RR is represented by a square and the corresponding 95%
CI are shown for the primary outcome(mRS-0-2) at 90 days. The square's size is proportional to the study's weight in the meta-analysis implying studies with larger squares have greater
weight. The diamond beneath is the overall pooled estimate and its width denotes the 95% CI around the combined effect size.

Combined data(n=1	12)								
	Ínten	sive	Conventi	ional			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weigh	t M−ŀ	H, Random, 95% C	l Ye	ear M-H, Random, 95% Cl
Goyal et al 2017	0	10	30	130	0.5%	6	0.20 [0.01, 2.98] 20	
Anadani et al 2019	150	942	67	259	15.3%	6	0.62 [0.48, 0.79] 20	019 -
Cernik D et al 2019	88	376	101	314	15.6%	6	0.73 [0.57, 0.93] 20	019
Chang et al 2019	5	48	6	42	2.8%	6	0.73 [0.24, 2.22] 20	019
Eva A. Mistry et al 2019	20	179	59	267	9.6%	6	0.51 [0.32, 0.81	20	019 —
Anadani et al 2020	84	540	91	479	14.8%	6	0.82 [0.63, 1.07	20	
Han et al 2021	21	96	12	83	6.6%	6	1.51 [0.79, 2.89	1 20	021
Mazighi et al 2021	29	152	21	153	8.79	6	1.39 [0.83, 2.33	1 20	021
Yang et al 2022	66	406	61	408	13.49	6	1.09 [0.79, 1.50	1 20)22
Mistry et al 2023	7	37	20	76	5 19	6	0 72 [0 33 1 55	1 200	123
Nam et al 2023	12	155	8	147	4 39	6	1 42 [0 60 3 38	1 20	123
P. Upadhyaya et al 2023	5	44	9	59	3.3%	6	0.74 [0.27, 2.07	20	23
Total (95% CI)	407	2985	105	2417	100.0%	6	0.83 [0.68, 1.02	1	•
l otal events	487		485			= = = (
Heterogeneity: $Tau^2 = 0.1$	05; Chi [*] =	22.93	, df = 11 (I)	P = 0.02	2); I ^e =	52%			0.01 0.1 1 10 10
Test for overall effect: Z =	= 1.76 (P	= 0.08))						Favours intensive Favours conventional
Observational Stud	ies(n=8)							
	Intensive	Árm (Convention	al Arm			Odds Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Tota	Weigh	t M-H	l, Random, 95% Cl	Year	ır M-H, Random, 95% CI
Goyal et al 2017	0	10	30	130	0.5	%	0.20 [0.01, 2.98]	2017	7
Chang et al 2019	5	48	6	42	2.8	%	0.73 [0.24, 2.22]	2019	9
Eva A. Mistry et al 2019	20	179	59	267	12.0	%	0.51 [0.32, 0.81]	2019	9
Anadani et al 2019	150	942	67	259	24.9	%	0.62 [0.48, 0.79]	2019	9
Cernik D et al 2019	88	376	101	314	25.7	%	0.73 [0.57, 0.93]	2019	9
Anadani et al 2020	84	540	91	479	23.5	%	0.82 [0.63, 1.07]	2020	
Han et al 2021	21	96	12	83	7.5	% 2/	1.51 [0.79, 2.89]	2021	
r. Opaunyaya et al 2025	5	44	9	59	5.5	/0	0.74 [0.27, 2.07]	2025	5
Total (95% CI)		2235		1633	100.09	%	0.72 [0.59, 0.87]		◆
Total events	373		375						
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 10$.48, df	= 7 (P = 0.1)	$(16); 1^2 =$	33%				0.01 0.1 1 10 10
Test for overall effect: $Z = 3$.35 (P = 0	.0008)							Favours Intensive Control Favours Conventional
RCTs(n=4)									
Inte	ensive Cor	ntrol	Conventio	nal Con	trol		Risk Ratio		Risk Ratio
Study or Subgroup E	vents	Tota	Events		Total V	Veight	M-H, Random, 9	5% CI	I Year M-H, Random, 95% CI
Mazighi et al 2021	29	152	21		153	22.7%	1.39 [0.83,	2.33]] 2021
Yang et al 2022	66	406	61		408	58.9%	1.09 [0.79,	1.50]	2022
Mistry et al 2023	7	37	20		76	10.3%	0.72 [0.33,	1.55]	2023
Nam et al 2023	12	155	8		147	8.0%	1.42 [0.60,	3.38]	2023
Total (95% CI)		750			784 1	.00.0%	1.13 [0.88,	1.44]	1 🔶
Total events	114		110	1					
Heterogeneity: $Tau^2 = 0.00$	0; Chi ² = 2	.29, df	= 3 (P = 0.	51); $I^2 =$	0%				
Test for overall effect: Z =	0.95 (P =	0.34)							U.UI U.I I 10 10 Favours Intensive Favours Conventional

2 Figure-3-Forest plot for the outcome of death at 90 days

Legend-The estimated risk ratio-RR is represented by a square and the corresponding 95%
CI are shown for the outcome death at 90 days. The square's size is proportional to the study's weight in the meta-analysis implying studies with larger squares have greater weight.
The diamond beneath is the overall pooled estimate and its width denotes the 95%CI around the combined effect size.

Combined data(n=9)

	Intens	sive	Convent	tional		Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Rando	om, 95% CI	
Goyal et al 2017	1	10	7	130	2.4%	1.86 [0.25, 13.64]	2017			-	
Anadani et al 2019	37	942	20	259	18.2%	0.51 [0.30, 0.86]	2019				
Anadani et al 2020	16	540	29	479	15.9%	0.49 [0.27, 0.89]	2020				
Han et al 2021	19	96	16	83	15.9%	1.03 [0.57, 1.86]	2021		_	<u> </u>	
Mazighi et al 2021	17	154	11	157	12.6%	1.58 [0.76, 3.25]	2021		-	-	
Yang et al 2022	23	407	25	409	17.4%	0.92 [0.53, 1.60]	2022				
Mistry et al 2023	2	37	3	72	3.1%	1.30 [0.23, 7.43]	2023			· · · · ·	
Nam et al 2023	14	155	12	149	12.3%	1.12 [0.54, 2.34]	2023				
P. Upadhyaya et al 2023	1	44	4	59	2.1%	0.34 [0.04, 2.90]	2023				
Total (95% CI)		2385		1797	100.0%	0.84 [0.61, 1.16]			•		
Total events	130		127								
Heterogeneity: Tau ² = 0.08	8; Chi ² =	12.13,	df = 8 (P	= 0.15); $I^2 = 34$	%		0.01	0 1	10	10
Test for overall effect: $Z =$	1.07 (P =	= 0.29)						0.01	Favours Intensive	Favours Conve	ntional

Observational Studies(n=5)

	Intensive C	ontrol	Convent	tional		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Random, 95% CI	Year		M-H, Rand	om, 95% CI		
Goyal et al 2017	1	10	7	130	3.9%	1.86 [0.25, 13.64]	2017					
Anadani et al 2019	37	942	20	259	34.1%	0.51 [0.30, 0.86]	2019					
Anadani et al 2020	16	540	29	479	29.2%	0.49 [0.27, 0.89]	2020					
Han et al 2021	19	96	16	83	29.3%	1.03 [0.57, 1.86]	2021			—		
P. Upadhyaya et al 2023	1	44	4	59	3.4%	0.34 [0.04, 2.90]	2023					
Total (95% CI)		1632		1010	100.0%	0.64 [0.43, 0.96]			•			
Total events	74		76									
Heterogeneity: $Tau^2 = 0.0$	5; Chi ² = 5.37	, df = 4	(P = 0.25)	5); $I^2 = 2$	26%				0 1	10	10	
Test for overall effect: Z =	2.15 (P = 0.0)	3)						0.01	Favours Intensive	Favours Conver	ntional	

RCTs(n=4)

	Intensive	e Arm	Conventiona	l Arm		Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Raı	ndom, 95%	S CI	
Mazighi et al 2021	17	154	11	157	25.8%	1.58 [0.76, 3.25]	2021					
Yang et al 2022	23	407	25	409	44.9%	0.92 [0.53, 1.60]	2022		-	-		
Nam et al 2023	14	155	12	149	24.9%	1.12 [0.54, 2.34]	2023		-			
Mistry et al 2023	2	37	3	72	4.5%	1.30 [0.23, 7.43]	2023					
Total (95% CI)		753		787	100.0%	1.13 [0.78, 1.63]				•		
Total events	56		51									
Heterogeneity: Tau ² =		0.01	0 1	1	10	10						
Test for overall effect:		0.01	Favours Intensi	Favours	Conventio	unal 10						

2 Figure-4- Forest plot for the outcome of symptomatic ICH(sICH)

3 Legend-The estimated risk ratio-RR is represented by a square and the corresponding 95% 4 CI are shown for the outcome sICH. The square's size is proportional to the study's weight in 5 the meta-analysis implying studies with larger squares have greater weight. The diamond 6 beneath is the overall pooled estimate and its width denotes the 95%CI around the combined 7 effect size.

8

1

- 9
- 10
- 11
- 12
- 13
- 14
- 15

- 17
- 18
- 19
- 20
- 21
- 22

Combined data(n=4)

Intensive			Convent	ional		Risk Ratio			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Rand	om, 95% Cl			
Anadani et al 2019	31	942	19	259	53.6%	0.45 [0.26, 0.78]	2019						
Anadani et al 2020	11	540	34	479	40.9%	0.29 [0.15, 0.56]	2020						
Mazighi et al 2021	1	158	0	162	2.3%	3.08 [0.13, 74.93]	2021						
P. Upadhyaya et al 2023	1	44	1	59	3.2%	1.34 [0.09, 20.85]	2023						
Total (95% CI)		1684		959	100.0%	0.40 [0.25, 0.66]			+				
Total events	44		54										
Heterogeneity: $Tau^2 = 0.0$	4; $Chi^2 =$	3.43, 0	df = 3 (P =	= 0.33);	$l^2 = 13\%$	1		-		10			
Test for overall effect: Z =	3.60 (P =	= 0.000)3)					0.01	Favours Intensive	Favours Conventi	onal		

Observational Studies(n=3)

	Intensive Conventional					Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Randon	n, 95% Cl			
Anadani et al 2019	31	942	19	259	57.9%	0.45 [0.26, 0.78]	2019					
Anadani et al 2020	11	540	34	479	39.8%	0.29 [0.15, 0.56]	2020					
P. Upadhyaya et al 2023	1	44	1	59	2.4%	1.34 [0.09, 20.85]	2023		•			
Total (95% CI)		1526		797	100.0%	0.39 [0.25, 0.59]		•				
Total events	43		54									
Heterogeneity: $Tau^2 = 0.0$	0; Chi ² =	1.85, 0	df = 2 (P)	= 0.40);	$l^2 = 0\%$		to to	01 01	10	100		
Test for overall effect: Z =	4.43 (P -	< 0.000	001)				0.	Favours Intensive Control Fa	avours Conventional	100		

3 Figure-5- Forest plot for the outcome of decompressive surgery.

Legend-The estimated risk ratio-RR is represented by a square and the corresponding 95% 5 CI are shown for the outcome requirement of decompressive surgery. The square's size is 6 proportional to the study's weight in the meta-analysis implying studies with larger squares 7 have greater weight. The diamond beneath is the overall pooled estimate and its width 8 denotes the 95%CI around the combined effect size.

1

Combined Analysis of n=7 studies(Intensive Control Cut-off=140mmHg)

	Intensive Management Conventional Management				Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I Year	M-H, Random, 95% CI	
Goyal et al 2017	7	10	67	130	9.1%	1.36 [0.88, 2.11	2017	+	
Anadani et al 2019	485	942	92	259	17.9%	1.45 [1.22, 1.73	2019	-	
Cernik D et al 2019	202	376	132	314	18.5%	1.28 [1.09, 1.50	2019	-	
Chang et al 2019	32	48	17	42	0.0%	1.65 [1.08, 2.50	2019		
Eva A. Mistry et al 2019	96	179	90	267	0.0%	1.59 [1.28, 1.98	2019		
Anadani et al 2020	283	540	222	479	19.7%	1.13 [1.00, 1.28	2020	-	
Han et al 2021	38	96	27	83	10.2%	1.22 [0.82, 1.81	2021		
Mazighi et al 2021	67	152	69	153	0.0%	0.98 [0.76, 1.26	2021		
Yang et al 2022	192	404	247	406	0.0%	0.78 [0.69, 0.89	2022		
P. Upadhyaya et al 2023	28	44	27	59	0.0%	1.39 [0.97, 1.99	2023		
Mistry et al 2023	17	37	36	76	9.5%	0.97 [0.64, 1.48	2023	+	
Nam et al 2023	61	155	80	147	15.2%	0.72 [0.57, 0.92	2023	-	
Total (95% CI)		2156		1488	100.0%	1.14 [0.96, 1.36	1	•	
Total events	1093		656						
Heterogeneity: Tau ² = 0.04	4; Chi ² = 23.28, d	if = 6 (P =	= 0.0007); I ² = 74	4%					
Test for overall effect: Z =	1.49 (P = 0.14)							Favours [conventional] Favours [intensive]	
Observational St	idies(n=5)-	Intens	ive Contro	l Cut-off	=140n	mHa			
Observational St	Intensive C	antrol	Conventional C	Cut-on	-1401	Rick Patio		Risk Patio	
Study or Subgroup	Events	Total	Events	Total We	iaht M.	H Random 95% Cl	Vear	M-H Bandom 95% Cl	
Coval et al 2017	7	10	67	120	E 20/	1 36 10 88 3 111	2017		
Goyal et al 2017	· · · · · · · · · · · · · · · · · · ·	10	07	150	3.3%	1.50 [0.88, 2.11]	2017		
Eva A. Mistry et al 2019	96	179	90	267	0.0%	1.59 [1.28, 1.98]	2019		
Anadani et al 2019	485	942	92	259 2	4.4%	1.45 [1.22, 1.73]	2019		
Cernik D et al 2019	202	376	132	314 2	7.4%	1.28 [1.09, 1.50]	2019	•	
Chang et al 2019	32	48	17	42	0.0%	1.65 [1.08, 2.50]	2019		
Anadani et al 2020	283	540	222	479 3	6.4%	1.13 [1.00, 1.28]	2020	•	
Han et al 2021	38	96	27	83	6.4%	1.22 [0.82, 1.81]	2021	+	
P. Upadhyaya et al 2023	28	44	27	59	0.0%	1.39 [0.97, 1.99]	2023		
Total (95% CI)		1964		1265 10	0.0%	1.26 [1.13, 1.40]		▲	

Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 5.47$, df = 4 (P = 0.24); $I^2 = 27\%$ RCTs(n=2)-Intensive Control Cut-off=140mmHg

1015

Test for overall effect: Z = 4.32 (P < 0.0001)

Total events

Intensive Control **Conventional Control Risk Ratio Risk Ratio** M-H. Random, 95% CI Study or Subgroup Total Total Weight M-H, Random, 95% CI Events Events Year Mazighi et al 2021 Yang et al 2022 67 152 69 153 0.0% 0.98 [0.76, 1.26] 2021 192 247 0.0% 0.78 [0.69, 0.89] 2022 404 406 67.8% Nam et al 2023 61 155 80 147 0.72 [0.57, 0.92] 2023 Mistry et al 2023 17 37 36 76 32.2% 0.97 [0.64, 1.48] 2023 Total (95% CI) 192 223 100.0% 0.79 [0.61, 1.04] Total events 78 116 Heterogeneity: Tau² = 0.01; Chi² = 1.39, df = 1 (P = 0.24); I² = 28% 0.01 100 10 0.1 Test for overall effect: Z = 1.67 (P = 0.09)Favours Conventional Favours Intensive

0.01

0.1

Favours Conventional Favours Intensive

10

100

Combined Analysis of studies(n=3) using a SBP cut-off of 130mmHg (mRS 0-2@90d) for intensive control

540

	Intensive Manag	gement	Conventional Man	agement		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Goyal et al 2017	7	10	67	130	0.0%	1.36 [0.88, 2.11]	2017	
Anadani et al 2019	485	942	92	259	0.0%	1.45 [1.22, 1.73]	2019	
Cernik D et al 2019	202	376	132	314	0.0%	1.28 [1.09, 1.50]	2019	
Chang et al 2019	32	48	17	42	27.9%	1.65 [1.08, 2.50]	2019	
Eva A. Mistry et al 2019	96	179	90	267	0.0%	1.59 [1.28, 1.98]	2019	
Anadani et al 2020	283	540	222	479	0.0%	1.13 [1.00, 1.28]	2020	
Han et al 2021	38	96	27	83	0.0%	1.22 [0.82, 1.81]	2021	
Mazighi et al 2021	67	152	69	153	40.1%	0.98 [0.76, 1.26]	2021	+
Yang et al 2022	192	404	247	406	0.0%	0.78 [0.69, 0.89]	2022	
P. Upadhyaya et al 2023	28	44	27	59	32.0%	1.39 [0.97, 1.99]	2023	
Mistry et al 2023	17	37	36	76	0.0%	0.97 [0.64, 1.48]	2023	
Nam et al 2023	61	155	80	147	0.0%	0.72 [0.57, 0.92]	2023	
Total (95% CI)		244		254	100.0%	1.27 [0.92, 1.74]		•
Total events	127		113					
Heterogeneity: Tau ² = 0.0	5; Chi ² = 5.45, df	= 2 (P =	0.07 ; $l^2 = 63\%$					
Test for overall effect: Z =	1.44 (P = 0.15)							0.01 0.1 I 10 100
								ravours (conventional) ravours (intensive)

² 3

Figure-6-mRS 0-2 at 90 days with different SBP cut-off to define intensive control

4 Legend- The estimated risk ratio-RR is represented by a square and the corresponding 95%

5 CI are shown for the primary outcome(mRS-0-2) at 90 days. The square's size is proportional

6 to the study's weight in the meta-analysis implying studies with larger squares have greater

weight. The diamond beneath is the overall pooled estimate and its width denotes the 95% CI 7

8 around the combined effect size.